AbbVie (ABBV) Stock Forecast & Price Target

AbbVie is likely to see continued strong performance in its immunology and oncology portfolios, driven by Skyrizi and Rinvoq, and potential new drugs in the pipeline such as Bretisilocin and IMGN151. The recent acquisitions of Cerevel and ImmunoGen further expand and diversify AbbVie's product offerings. With strong financials, a solid pipeline, and a focus on access and affordability, AbbVie is well positioned for continued growth and success.

AbbVie is facing numerous challenges, including pricing pressures, supply chain vulnerabilities, and product liability risks, which require careful risk management to sustain shareholder value. Furthermore, the company's recent acquisitions may not be enough to offset declining sales in its immunology business due to increasing competition and pipeline setbacks, leading to a deteriorating base business growth and declining earnings per share. Additionally, AbbVie's governance structure, while striving to balance shareholder returns and public health interests, may not be enough to mitigate potential legal and reputational risks.